iTeos Therapeutics, Inc.
Net SellingITOS·US·🇺🇸 US
9%buys·91%sales
2,263 transactions$727.0MTotal buys·139 buys
$928.5MTotal sells·1,351 sells
4343 insiders
Last: Aug 29, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Aug 29, 25 | RHOADS ANN D | Disposition | - | |
| Aug 29, 25 | Hallal David | Disposition | - | |
| Aug 29, 25 | Hallal David | Disposition | - | |
| Aug 29, 25 | McGrath Yvonne | Disposition | - | |
| Aug 29, 25 | McGrath Yvonne | Disposition | - | |
| Aug 29, 25 | McGrath Yvonne | Disposition | - | |
| Aug 29, 25 | Gall Matthew | Disposition | - | |
| Aug 29, 25 | Gall Matthew | Disposition | - | |
| Aug 29, 25 | Gall Matthew | Disposition | - | |
| Aug 29, 25 | Gall Matthew | Disposition | - |
iTeos Therapeutics, Inc. (ITOS) has recorded 2 263 insider transactions from 43 insiders. Total insider buying volume stands at $727.0M, while total selling volume is $928.5M. Overall insider sentiment is bearish (91% sales).
iTeos Therapeutics, Inc. (ITOS) has recorded 2 263 insider operations, including 139 open-market purchases ($727.0M), 1 351 sales ($928.5M) and 773 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (91% sales).
iTeos Therapeutics, Inc. shows moderate insider activity with 6 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are Detheux Michel (CEO), Gall Matthew (CFO) & McGrath Yvonne (C SUITE), with respectively 116, 21, 34 transactions.
Across all 2 263 recorded transactions, the breakdown by type is: sales (1351, 60%), exercise (568, 25%), buys (139, 6%), grant (98, 4%), other (65, 3%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
iTeos Therapeutics, Inc. has recorded 2 263 insider operations in total, including 139 open-market purchases ($727.0M), 1 351 sales ($928.5M) and 773 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on August 29, 2025.
Insiders at iTeos Therapeutics, Inc. are currently net sellers, with 9% purchases and 91% sales across all reported transactions. Total buy volume is $727.0M versus $928.5M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 43 insiders at iTeos Therapeutics, Inc. (ITOS). Detheux Michel (CEO, 116 tx), Gall Matthew (CFO, 21 tx), McGrath Yvonne (C SUITE, 34 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for ITOS is bearish, based on a 9% buy ratio across 1 490 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for iTeos Therapeutics, Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.